MK-677 vs Turinabol
Well Studied vs Moderate Research
avoid Mechanism-based · 64% Both MK-677 and Turinabol carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
MK-677 Turinabol
Weight 624.77 Da 334.88 Da
Half-life ~24 hours ~16 hours
Type Non-peptide ghrelin receptor agonist 17-alpha-alkylated anabolic-androgenic steroid (C20H27ClO2)
Key Benefits
MK-677
01 97% increase in 24-hour growth hormone secretion
02 40-72% elevation in IGF-1 levels
03 Enhanced sleep quality with improved REM patterns
04 Preferential lean tissue gains of 1.1-2.7kg over 8-12 months
05 15% basal metabolic rate increase within 2 weeks
06 Oral administration (no injections required)
Turinabol
01 Promotes lean, dry muscle gains without water retention or bloating
02 Does not aromatize to estrogen, eliminating risk of gynecomastia and estrogen-related side effects
03 Favorable anabolic-to-androgenic ratio, reducing androgenic side effects relative to muscle-building potential
04 Enhances muscular endurance and recovery through increased red blood cell production
05 Increases strength without significant body weight gain, beneficial for weight-class athletes
06 Improves creatine phosphate resynthesis, supporting repeated high-intensity efforts
07 Relatively mild androgenic profile compared to most oral anabolic steroids
08 Produces slow, steady, maintainable gains rather than rapid temporary increases
Side Effects
MK-677
Appetite stimulation (>50% of users)
Water retention (30-40%)
Lethargy (20-30%)
Fasting glucose elevation (5-15mg/dL)
Note on testosterone suppression: at doses up to 20 mg daily, MK-677 is unlikely to cause significant testosterone suppression on its own. Above 20 mg daily, the likelihood of suppression and other side effects (insulin resistance, water retention, lethargy) increases. The case report documenting 85.7% testosterone suppression involved co-administration with LGD-4033, a SARM known to be profoundly suppressive, making the SARM the likely primary driver of that suppression.
Turinabol
Hepatic stress with elevated liver enzymes (ALT, AST) -- moderate severity, dose- and duration-dependent
HDL cholesterol suppression (significant, often 30-50% reduction)
LDL cholesterol elevation
Suppression of endogenous testosterone production via HPG axis negative feedback
Mild gastrointestinal discomfort or nausea
Back pumps (lower back tightness during exercise, common with 17-alpha-alkylated compounds)
Oily skin and mild acne
Decreased appetite in some users
Contraindications
Heart disease or congestive heart failure
Diabetes or pre-diabetes
Active cancer
Severe cardiovascular disease
Pregnancy or breastfeeding
Known or suspected prostate cancer
Breast cancer in males
Pregnancy or planned pregnancy (teratogenic risk)
Active liver disease or significant hepatic impairment
Pre-existing severe dyslipidemia or cardiovascular disease
Hypersensitivity to turinabol or related compounds
Research Evidence
MK-677 Turinabol
Status Well Studied Moderate Research
References 7 studies 5 studies
Latest July 2024 June 2023
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.